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Understanding the clinical manifestations of 16p11.2 deletion 
syndrome: a series of developmental case reports in children
Rana Fetita, David J. Pricea, Stephen M. Lawrieb and Mandy Johnstoneb 
Background Copy number variants (CNVs) are genetic 
rearrangements, such as deletions and duplications, 
which result in a deviation from the normal number of 
copies of a given gene segment. CNVs are implicated 
in many neuropsychiatric disorders. Deletions of the 
human chromosomal region 16p11.2 are one of the most 
common genetic linkages to autism spectrum disorders 
(ASD). However, ASD is not the only presenting feature, 
and many patients with 16p11.2 deletions present with a 
variable clinical spectrum.
Methods To better understand the nature and 
presentation of the syndrome throughout development, 
we present three different, unrelated clinical cases of 
children with 16p11.2 deletion and provide a detailed 
description of their clinical manifestations.
Results Cognitive and motor impairments were 
characteristic of all three patients with 16p11.2 deletion, 
despite the differences in the extent and clinical 
presentation of impairment. Two patients had a clinical 
diagnosis of ASD and one showed several ASD traits. 
In addition, two patients also had severe speech and 
language impairments, which is in line with previous 
reports on 16p11.2 phenotypes. Although epilepsy and 
obesity have been frequently associated with 16p11.2 
deletion, only one patient had a diagnosis of epilepsy and 
none of the three cases were obese.
Conclusion This variation in clinical phenotype renders 
correct clinical interpretation and diagnosis challenging. 
Therefore, it is critical to elucidate the variable clinical 
phenotypes of rare CNVs, including 16p11.2 deletions, to 
help guide clinical monitoring and counselling of patients 
and families. Psychiatr Genet 30: 136–140 Copyright © 
2020 The Author(s). Published by Wolters Kluwer Health, Inc.
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Introduction
Copy number variants (CNVs) represent recurrent chro-
mosomal abnormalities and are associated with various 
phenotypic features (Lupski, 1998; Shinawi et al., 2010; 
Jensen and Girirajan, 2019). Chromosome 16 is particu-
larly rich in highly homologous low-copy repeats (LCRs), 
that mediate such genetic rearrangements via LCR-
mediated nonallelic homologous recombination events 
during meiosis (Loftus et al., 1999; Stankiewicz and 
Lupski, 2002; Martin et al., 2004). Deletions of the human 
chromosomal region 16p11.2 are one of the most common 
genetic linkages to autism spectrum disorders (ASD) and 
account for approximately 1% of the cases (Kumar et al., 
2008; Weiss et al., 2008; Fernandez et al., 2010). Indeed 
patients with duplications of 16p11.2 appear to have a 
similar odds ratio to developing ASD as 16p11.2 dele-
tions but interestingly the duplication carriers have a 
higher odds ratio of developing attention deficit hyper-
activity disorder and a higher frequency of developing 
overall psychiatric disorders and psychosis (Niarchou et 
al., 2019). However, ASD is not the only presenting fea-
ture in many patients with 16p11.2 deletion and only 
25% of individuals with the deletion exhibit an autism 
phenotype (Hanson et al.; Jensen and Girirajan, 2019). 
16p11.2 deletions are associated with a variable clinical 
spectrum of neurocognitive phenotypes and many other 
patients may manifest intellectual disability, morbid 
obesity, large head circumference, or epilepsy at varying 
degrees of penetrance (Bijlsma et al., 2009; Bochukova 
et al., 2010; Shinawi et al., 2010). Even unaffected carri-
ers of these CNVs are associated with cognitive deficits 
which may be subtle but confer significant disadvantages 
in educational attainment and ability to earn income in 
adulthood (Kendall et al., 2019) as well as resulting in pro-
found effects on physical health and mortality, even in 
those who have less profound early neurodevelopmental 
consequences (Crawford et al., 2019). Early identification 
is therefore vital to allow appropriate medical and neu-
ropsychiatric screening, support and treatment through-
out the lifespan.
As with other microdeletion syndromes, the clinical 
heterogeneity and incomplete penetrance in 16p11.2 
patients are quite remarkable which renders correct 
This is an open access article distributed under the Creative Commons Attribution 
License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduc-
tion in any medium, provided the original work is properly cited.
Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Case reports of children with 16p11.2 microdeletions Fetit et al. 137
clinical interpretation and diagnosis challenging. To pro-
vide patients with a better clinical experience and ensure 
an enhanced developmental outcome, 16p11.2 dele-
tion cases should be thoroughly phenotyped clinically. 
Several studies have presented a detailed phenotypic 
characterisation of individuals with 16p11.2 imbalances 
at the time of diagnosis revealing a variable clinical spec-
trum of neurocognitive phenotypes which included mac-
rocephaly, developmental and language delay, cognitive 
impairment, as well as seizures (Fernandez et al., 2010; 
Hanson et al., 2010; Shinawi et al., 2010). Another study 
has provided an elaborate description of the neurologic 
phenotypes of 16p11.2 deletion cases via comprehensive 
neurologic evaluation showing that despite the overlap 
with other neurodevelopmental disorders, speech and 
motor impairments, growth abnormalities, and tremors 
are striking features of 16p11.2 deletions that clinicians 
should be aware of (Steinman et al., 2016). Here, we pres-
ent three different, unrelated clinical cases of children 
with 16p11.2 deletion and provide a detailed description 
of their clinical manifestations from birth and through-
out development. Despite the limited number of cases 
described here, presenting the complete developmental 
history and progression of the symptoms will help better 
understand the nature and presentation of the syndrome 
throughout development and thereby assist in accurate 
clinical diagnosis and early interventions.
Methods
This study was approved by the School of Philosophy, 
Psychology and Language Sciences (PPLS) Research 
Ethics Committee of the University of Edinburgh (ref-
erence number 286-1819/2). Participants were recruited 
through online platforms, such as Simons Variation in 
Individuals Project (Simons VIP) connect social group. 
A thorough explanation of the study was provided to 
the guardians of the three children, and they gave their 
informed consent to participate. Parents were then 
interviewed in person or through video chat (example: 
Skype) if they were not residents of the UK, and were 
asked questions on (1) the clinical symptoms of their 
children throughout development, (2) any medications 
being taken, (3) any relevant family history and finally (4) 
social/clinical measures taken by parent/guardian since 
diagnosis with 16p11.2 deletion.
Results
Case 1
An 11-year-old girl presented with a diagnosis of hyper-
mobility, memory retention difficulties (both short-term 
and long-term), social difficulties and epilepsy. At birth, 
she was reported to have a large head circumference. At 
6 months of age, she had her first epileptic seizure and 
continued to have episodes every other month until she 
was diagnosed with generalised idiopathic tonic-clonic 
epilepsy. At 13 months, she was administered sodium 
valproate (Epilim) for the treatment of epilepsy. At 16 
months, her parent started noticing signs of impaired 
mobility, such as lack of balance and frequent falling. 
By 3 years of age, her valproate medication was stopped 
because she had stopped having seizures but this resulted 
in a longer seizure that kept reoccurring over a period of 
7 h. She was treated with phenytoin and put back on her 
former medication.
At school, this patient started showing signs of delayed 
learning and impaired memory retention as well as 
weight fluctuations. Symptoms of impaired mobility 
(imbalance, inward toeing while walking and contin-
uous falling) still persisted and at 8 years old, she was 
diagnosed with hypermobility. By the age of 9, she was 
referred to an endocrinologist who offered genetic test-
ing. Array comparative genomic hybridisation revealed 
a deletion in the proximal region of the genomic locus 
16p11.2 (29 673 953–30 198 600), spanning approximately 
524 kb. At this time, the patient continues to have mod-
erate–severe learning and memory impairments. She is 
also presented with several ASD traits, although no offi-
cial ASD diagnosis has been made. For example, she 
struggles with change of routine and gets emotionally 
attached to objects. Moreover, she has sensory difficul-
ties. She dislikes loud noises, music or over-populated 
areas. The patient also struggles with social nuance and 
social cues. According to her parent, she has a very low 
opinion of herself and struggles to regulate her emotions. 
Her parent also continues to notice absence seizures, but 
no official diagnosis has been made.
Case 2
A 5-year-old girl presented with a diagnosis of ASD, 
developmental delay, speech delay and anxiety. The 
mother was reported to have complications during preg-
nancy. She haemorrhaged the night before her due date 
and the following afternoon she was induced. At birth, the 
child had low birth weight (2.88 kg) and was supported in 
a temperature-controlled incubator. At the age of 3, her 
parents started noticing signs of speech and motor delay; 
however, a diagnosis of ASD was not met at this stage. 
She was then supported by an occupational therapist, 
to develop and strengthen fine and gross motor skills. 
However, at 4 years, she was diagnosed with ASD, global 
delay and anxiety and was offered genetic testing by her 
paediatrician. Molecular karyotyping results revealed a 
deletion in chromosome 16, region 16p11.2 (29 634 212–
30 199 805). This spans approximately 565 kb. Currently, 
she is not on any medications. Her parents have taken 
environmental measures to ensure appropriate lighting 
and noise and provided her with weighted and sensory 
toys. The patient continues to show speech and motor 
impairments, with no reports of seizures.
Case 3
An 8-year-old boy presented with a diagnosis of ASD 
together with childhood apraxia of speech. He was born 
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with low birth weight (2.60 kg) and slight macrocephaly. 
From 3 to 6 months, he kept losing weight. Between 6 
and 10 months, he was diagnosed with rickets and was 
given vitamin D supplements. By the age of 2, the 
patient showed symptoms of social and emotional delay 
and was offered occupational therapy, physical therapy 
and speech therapy. He was then referred to a neurolo-
gist who diagnosed him with ASD around the age of 3. 
The patient also showed severe language impairments, 
whereby the age of 3 he could only speak three words 
and communicated with his parents through sign lan-
guage for 2 years. He was also reported to have a few epi-
sodes of febrile seizures; however, EEG tests showed no 
signs of epilepsy and seizures resolved during childhood. 
Following that, he was offered genetic testing by his pae-
diatrician. Chromosomal microarray analysis revealed a 
deletion in the short arm of chromosome 16; particularly 
at the region 16p11.2 (29 567 295–30 177 916) which spans 
approximately 611 kb.
Between 4 and 5 years, the patient started exhibiting 
repetitive movements as well as verbal/phonetic tics trig-
gered by calling his name. This included foot rubbing to 
full leg rubbing, refusing to walk on lines and not being 
able to walk through light beams shining through a win-
dow. Currently, he is not on any medications. He has a 
poor muscle tone, slight scoliosis and continues to show 
speech and language impairments.
Discussion
Recurrent 16p11.2 deletions are characterised by a spectrum 
of neurocognitive phenotypes that are variably expressed 
amongst patients. We describe herein the phenotypes of 
three subjects with the deletion of the genomic region 
within chromosome 16p11.2. Table 1 provide a summary of 
the different clinical manifestations and clinical data of the 
patients together with the genetic locus of the deletions. 
The effects of 16p11.2 deletion on mean intelligence quo-
tient have been shown to be a decrease of approximately 2 
SDs (D’Angelo et al., 2016; Hippolyte et al., 2016) and intel-
lectual disability is more frequent amongst deletion carriers 
(Niarchou et al., 2019). Similarly, 16p11.2 deletion carriers 
showed the worst performance in a series of cognitive tests 
and were associated with statistically significant reductions 
in the number of offspring, suggesting deficits in socialising 
and forming families, as a consequence of cognitive, medical 
and behavioural problems (Kendall et al., 2019). Cognitive 
and motor impairments were characteristic of all three 
patients with 16p11.2 deletion, despite the differences in 
extent and clinical presentation of impairment. This is in 
line with the clinical findings of other studies on 16p11.2 
deletion carriers (Hanson et al., 2010, 2015; Shinawi et al., 
2010; Zufferey et al., 2012). The 16p11.2 deletion has been 
repeatedly associated with ASD, and accounts for approxi-
mately 1% of ASD cases (Weiss et al., 2008; Kumar et al., 2008; 
Fernandez et al., 2010). Moreover, ASD has been shown to 
be the second most prevalent diagnosis in 16p11.2 deletion 
carriers (Niarchou et al., 2019). In this study, two patients 
had a clinical diagnosis of ASD and one showed several ASD 
traits. Two of the patients also had severe speech and lan-
guage impairments, which have been reported in previous 
phenotypic characterisation of patients with 16p11.2 dele-
tions (Shimojima et al., 2009; Hanson et al., 2010; Shinawi 
et al., 2010; Schaaf et al., 2011; Zufferey et al., 2012). The 
16p11.2 deletion region has also been associated with obe-
sity (Kumar et al., 2008; Bochukova et al., 2010; Walters et 
al., 2010), but none of the three cases described here were 
obese. On the other hand, two patients were reported to be 
born with very low birthweights and weight fluctuations 
during early childhood. Although epilepsy is the most fre-
quent neurological disorder observed in 16p11.2 deletion 
carriers (Shimojima et al., 2009; Hanson et al., 2010; Shinawi 
et al., 2010; Schaaf et al., 2011; Zufferey et al., 2012), only 
one patient had a diagnosis of epilepsy whereas the other 
two had no reports of seizures or seizures had resolved with 
age. Similarly, previous reports have shown that congenital 
anomalies, including vertebral and spinal-related anomalies 
(Zufferey et al., 2012), to be strongly associated with dele-
tion carriers, scoliosis was reported in only one patient.
All three patients had deletion in the proximal region of the 
16p11.2 locus (Fig. 1). This genomic region spans around 
Table 1 Summary of clinical data of the three cases throughout development
Case 1 Case 2 Case 3
Premature birth No (1 day before due date) No (1 day after due date) No
Birth weight Average (3.30 kg) Low (2.88 kg) Low (2.60 kg)
Head circumference at birth N/Aa 33.3 cm N/Aa
Cognitive impairment Yes: moderate-severe learning and memory impairments Yes: global developmental delay, anxiety Yes: social and emotional delay
Motor impairments Yes: hypermobility, imbalance, inward-towing Yes: motor delay Yes: poor muscle tone
Language impairments None Yes: speech delay Yes: childhood apraxia of 
speech
Childhood illnesses diagnosed Hypermobility, memory retention and social difficulties, 
generalised idiopathic tonic-clonic epilepsy
ASD, developmental delay, speech delay 
and anxiety
ASD, childhood apraxia of 
speech, rickets
ASD diagnosis No (but shows some traits) Yes Yes
Seizures Yes: generalised idiopathic tonic-clonic epilepsy None Resolved: Febrile seizures
Medications Sodium valproate (Epilim) None None
Age at genetic testing 9 years 4 years 3 year
Deletion locus 16p11.2 (29 673 953–30 198 600) 16p11.2 (29 634 212–30 199 805) 16p11.2 
(29 567 295–30 177 916)
aN/A = measurements unavailable.
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600 kb and contains 47 genes, 28 of which are protein-coding. 
The flanking LCRs each span 147 kb and contain six dupli-
cated genes, five of which are annotated as protein-coding 
(Weiss et al., 2008; Jacquemont et al., 2011; Tai et al., 2016). 
NAHR-mediated CNV formation in vivo involves the mis-
pairing of the flanking LCRs, which can result in either the 
loss or gain of a 740-kb segment equivalent to one copy of 
the 593-kb segment and one copy-equivalent of the LCR 
(Walters et al., 2010). Several studies have demonstrated a 
dosage effect of 16p11.2 copy number on the various clin-
ical findings, suggesting the presence of dosage-sensitive 
genes within the region (Weiss et al., 2008; Shinawi et al., 
2010; Blumenthal et al., 2014). Moreover, several genes 
within the 16p11.2 are promising candidates for the varia-
ble phenotypes reported in patients with the deletion. For 
example, MAPK3 is a synaptic signalling component which 
is reported to be necessary for several forms of learning 
(Mazzucchelli et al., 2002; Pucilowska et al., 2015) and quin-
olinate phosphoribosyltransferase encodes a key enzyme in 
catabolism of quinolinate, a potent endogenous exitotoxin 
to neurons, the elevation of which has been linked to the 
pathogenesis of epilepsy (Feldblum et al., 1988; Haslinger 
et al., 2018). Polymorphisms in the TBX6 gene were asso-
ciated with congenital scoliosis in the Han population (Wu 
et al., 2015). Mice homozygous for a TBX6 mutation were 
also reported to show rib and vertebral body anomalies 
(Watabe-Rudolph et al., 2002), suggesting that TBX6 is a 
candidate gene for vertebral malformations. On a molecular 
level, knockdown and overexpression studies revealed the 
implications of several genes like MAPK3, KCTD13, MVP 
and TAOK2 that play critical roles in the growth and pro-
liferation of progenitor cells as well as neurite morphogen-
esis in the pathology of ASD (Golzio et al., 2012; de Anda 
et al., 2012; Pucilowska et al., 2015). Although the functions 
of other genes in this CNV remain poorly defined, these 
studies suggest that the dysregulation of cell cycle, neu-
ronal migration and cortical lamination is fundamental for 
the pathogenesis of neurodevelopmental disorders, includ-
ing ASD, in the developing brain (Hanson et al., 2010; de 
Anda et al., 2012; Packer, 2016; Casanova, 2014). Recently, 
it has been shown by modelling the 16p11.2 deletion in 
Drosophila melanogaster that a complex interaction of CNV 
genes operates in conserved pathways to modulate expres-
sion of the phenotype, many suppressing or enhancing 
cell proliferation pathways and are enriched in a human 
brain-specific network, providing translational relevance in 
humans (Iyer et al., 2018). It is suggested that this CNV has 
pleiotropic effects, given that it intersects multiple genes. 
Recently, significantly associated phenotypes and medical 
consequences to 16p11.2 deletion in adult carriers included 
a high incidence of diabetes, osteoarthritis, hypertension, as 
well as asthma, anaemia and renal problems, indicating the 
need for regular medical monitoring (Crawford et al., 2019).
In conclusion, it is clear that 16p11.2 deletions are mani-
fested in a wide range of clinical symptoms which gener-
ally include developmental and language delay, cognitive 
impairment, seizures and ASD. The variations in clinical 
phenotypes in patients with 16p11.2 deletion render cor-
rect clinical interpretation challenging and frequently 
results in delayed diagnosis. All three cases reported here 
were at least 3 years of age before they received genetic 
testing, which highlights the importance of establishing 
and implementing early routine diagnostic testing so that 
functional and physical health outcomes can be addressed 
and treated at the earliest opportunity to reduce the likeli-
hood of longer-term sequalae. As 16p11.2 deletion cannot 
be identified solely on the basis of clinical history, genetic 
testing should be a routine test in patients with neurode-
velopmental disorders showing symptoms of speech and 
language delay, intellectual disability, or a diagnosis of 
ASD. Therefore, elucidating the variable clinical pheno-
types of rare CNVs, including 16p11.2 deletions, remains 
critical to help guide clinical monitoring and counselling 
of patients and families.
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